- Home
- QLGN vs CMND Comparison
QLGN vs CMND Comparison
Compare QLGN & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QLGN
- CMND
- Stock Information
- Founded
- QLGN 1996
- CMND 2017
- Country
- QLGN United States
- CMND Canada
- Employees
- QLGN N/A
- CMND N/A
- Industry
- QLGN Biotechnology: Pharmaceutical Preparations
- CMND Biotechnology: Pharmaceutical Preparations
- Sector
- QLGN Health Care
- CMND Health Care
- Exchange
- QLGN Nasdaq
- CMND Nasdaq
- Market Cap
- QLGN 4.7M
- CMND 5.3M
- IPO Year
- QLGN N/A
- CMND N/A
- Fundamental
- Price
- QLGN $2.80
- CMND $1.03
- Analyst Decision
- QLGN
- CMND
- Analyst Count
- QLGN 0
- CMND 0
- Target Price
- QLGN N/A
- CMND N/A
- AVG Volume (30 Days)
- QLGN 2.5M
- CMND 2.5M
- Earning Date
- QLGN 07-21-2025
- CMND 09-15-2025
- Dividend Yield
- QLGN N/A
- CMND N/A
- EPS Growth
- QLGN N/A
- CMND N/A
- EPS
- QLGN N/A
- CMND N/A
- Revenue
- QLGN N/A
- CMND N/A
- Revenue This Year
- QLGN N/A
- CMND N/A
- Revenue Next Year
- QLGN N/A
- CMND N/A
- P/E Ratio
- QLGN N/A
- CMND N/A
- Revenue Growth
- QLGN N/A
- CMND N/A
- 52 Week Low
- QLGN $2.74
- CMND $0.80
- 52 Week High
- QLGN $13.50
- CMND $2.18
- Technical
- Relative Strength Index (RSI)
- QLGN 35.34
- CMND 53.10
- Support Level
- QLGN $2.77
- CMND $1.00
- Resistance Level
- QLGN $3.29
- CMND $1.25
- Average True Range (ATR)
- QLGN 0.53
- CMND 0.08
- MACD
- QLGN -0.06
- CMND 0.01
- Stochastic Oscillator
- QLGN 1.65
- CMND 30.82
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's program, QN-302, is an investigational small-molecule G-quadruplexes (G4)-selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells.
About CMND Clearmind Medicine Inc.
Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.